Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen and Company in a report released on Friday, Stock Ratings Network.com reports. They currently have a $17.00 price target on the stock. Cowen and Company’s price target suggests a potential upside of 22.74% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Brean Capital reiterated a “buy” rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research note to investors on Friday. They now have a $14.00 price target on the stock, down previously from $17.00. Separately, analysts at William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research note to investors on Friday. Finally, analysts at MKM Partners cut their price target on shares of Nektar Therapeutics (NASDAQ:NKTR) from $14.00 to $13.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $13.67.
Nektar Therapeutics (NASDAQ:NKTR) traded down 20.65% on Friday, hitting $10.99. 5,563,318 shares of the company’s stock traded hands. Nektar Therapeutics has a 52 week low of $5.65 and a 52 week high of $14.47. The stock has a 50-day moving average of $12.54 and a 200-day moving average of $11.21. The company’s market cap is $1.272 billion.
Nektar Therapeutics (NASDAQ:NKTR) last released its earnings data on Thursday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.07. The company had revenue of $33.86 million for the quarter, compared to the consensus estimate of $26.22 million. The company’s revenue for the quarter was up 43.0% on a year-over-year basis.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.